ArticleKidney international2020

In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

Abdelrhman Abumoawad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.